Therefore, the role of CDC6 in the progression of polycystic ovary syndrome to endometrial cancer by promoting immune infiltration may serve as a new tumor prognostic biomarker and a potential immunotherapy target. The gene discussed is CDC6; the disease is polycystic ovary syndrome.